Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2017
At a glance
- Drugs ACAM 529 (Primary) ; Valaciclovir
- Indications Herpes simplex virus type 2 infections
- Focus Adverse reactions; Pharmacodynamics
- 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 13 Oct 2015 New trial record